Outlook Therapeutics is a biopharmaceutical company that develops ophthalmic formulations.
Outlook Therapeutics has raised $5.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Outlook Therapeutics's investors include Perceptive Advisors, Great Point Partners, venBio Partners, Woodline Partners, Armistice Capital.
Outlook Therapeutics is headquartered in Iselin, United States.
Outlook Therapeutics is a biopharmaceutical company that develops ophthalmic formulations.
Outlook Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Outlook Therapeutics — Funding & Investors." VCBacked, April 22, 2026, https://www.vcbacked.co/company/outlook-therapeutics. Accessed November 12, 2026.
VCBacked. (2026). Outlook Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/outlook-therapeutics
{{cite web |title=Outlook Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/outlook-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Outlook Therapeutics? Request a listing update